Amgen (NAS:AMGN) Total Current Assets

: $48,477 Mil (As of Sep. 2023)

View and export this data going back to 1983. Start your Free Trial

Total current assets includes Cash And Cash Equivalents, Accounts Receivable, Total Inventories, and Other Current Assets. Amgen's total current assets for the quarter that ended in Sep. 2023 was $48,477 Mil.

Amgen Total Current Assets Historical Data

The historical data trend for Amgen's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

37,618.00

18,440.00

21,144.00

19,385.00

22,186.00

Amgen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Current Assets																24,062.00	22,186.00	44,703.00	47,380.00	48,477.00

Amgen Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Amgen's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash And Cash Equivalents	+	Accounts Receivable	+	Total Inventories	+	Other Current Assets
	=	9305	+	5563	+	4930	+	1559
	=	21,357

Amgen's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash And Cash Equivalents	+	Accounts Receivable	+	Total Inventories	+	Other Current Assets
	=	34741	+	6145	+	5026	+	2565
	=	48,477

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Amgen (NAS:AMGN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Amgen's Liquidation Value for the quarter that ended in Sep. 2023 is

	Liquidation value
=	Cash And Cash Equivalents	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	34741	-	82878	+	0.75 * 6145	+	0.5 * 5026
=	-41,015

Amgen Total Current Assets Related Terms

Thank you for viewing the detailed overview of Amgen's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (NAS:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (NAS:AMGN) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).

Executives

Matthew C. Busch	officer: VP, Finance & CAO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Michael V Drake	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Derek Miller	officer: SVP, Human Resources	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Rachna Khosla	officer: SVP, Business Development	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Amy E Miles	director
Linda H. Louie	officer: VP, Finance & CAO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Nancy A. Grygiel	officer: SVP & CCO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Peter H. Griffith	officer: EVP & CFO	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Murdo Gordon	officer: EVP Global Commercial Ops	C/O BRISTOL-MYERS SQUIBB COMPANY, 345 PARK AVE, NEW YORK NY 10154
David M Reese	officer: EVP, Research and Development	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Brian Druker	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Wanda M Austin	director	6001 BOLLINGER CANYON ROAD, SAN RAMON CA 94583
Charles M Holley	director
Lori A Johnston	officer: SVP, HR	C/O AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320